Keywords
central nervous system
neuropathologies
neuroprotection
neuroregeneration
How to Cite
Abstract
Neuropsychiatric diseases affect more than 10 % of the Cuban population and 25 % worldwide. Most drugs used to treat central nervous system disorders are expensive and create severe side reactions. Efforts are currently being developed for the implementation of secondary metabolites such as environmentally sustainable sources for the treatment of nervous system diseases, including stroke and other Parkinson’s-type neuropathologies, and Huntington’s motor disorders, enabling an effective neuroprotection as well as short periods of neuroregeneration time with minimal sequels. The objective was to evaluate the neuroprotective and neuroregenerative action of sodium salts of isolated resin acids from Cuban conifers. The study results suggest that the sodium salt of resin acids can be used as a structural bioisosteric isoanalogue precursor with specific therapeutic actions such as neuroregeneration and neuroprotection in the treatment of ischemic diseases.
References
Arteaga, Y., Carballo, L., Tiomno, O., Sotolongo, R., Tacoronte, J. E., & Hevia, Y. (2010). Colofonia de pináceas cubanas para el control de enfermedades tropicales transmitidas por moluscos. Revista Chapingo Serie Ciencias Forestales y del Ambiente 16(1), 31-36 http://redalyc.uaemex.mx/redalyc/pdf/629/62913391004.pdf
Arteaga, Y., Carballo, L., Tiomno, O., Casal, A., Tacoronte, J. E. & Cruz, R. (2007). Resina de pino: química verde y potencialidades biológicas. Revista Cubana de Química 19(1), 91-93
Arteaga, Y., Carballo, L., Tiomno, O., Casal, A., Tacoronte, J. E., & Cruz, R. (2009). Resina de pino: Materia prima renovable para la obtención de productos farmacológicos. CIGET Pinar del Río 11(3), 35-40
Ashton, CH., Moore, P. B., Gallagher, P., & Young, A. H. (2005). The endocannabinoid system as an emerging target of P pharmacotherapy. Journal Psychopharmacol 19(3), 293-300. doi: https://doi.org/10.1124/pr.58.3.2
Bradley, E. A. (2004). Endocannabinoids and their implications for epilepsy. Epilepsy curr. 4(5), 169-173.
Cardona, G. P., Arango, D. C., Gallego, G. J., Pimienta, H. & García, L. M. (2004). Estrogens inhibit glycogen synthase kinase-3b and modulates the interaction of the microtubule-associated protein Tau with glutamate receptor subunits in post-ischemic hippocampus: implications for hormonal neuroprotective mechanisms. Molecular Brain Research. 25,178-187.
Carrasco, G. A. & Van de Kar, L. (2003). Neuroendocrine pharmacology of stress. Eur. J. Pharmacol. 463, 235-272.
Chen, J., Lee C. T., Errico, S., Deng, X., Cadet, J. L., & Freed, W. J. (2005). Protective effects of delta(9)- tetrahydrocannabinol against N-methyl-d-aspartate-induced AF5 cell death. Molecular Brain Research 4; 134(2), 215-225 http://www.ncbi.nlm.nih.gov/pubmed/15836919
Cho, C. M., Hirsch, R., & Johnstone, S. (2005). General and oral health implications of cannabis use. Australian Dental Journal 50(2), 70-74. http://www.ncbi.nlm.nih.gov/pubmed/16050084
File, S. E. & Seth, P. (2003). A review of 25 years of the social interaction test European Journal of Pharmacology 463, 35-53. http://www.ncbi.nlm.nih.gov/pubmed/12600701
Garcia-Galloway, E., Arango, C., Pons, S., & Torres-Alemán, I. (2003). Glutamate excitotoxicity attenuates insulin-like growth factor-I prosurvival signaling. Molecular and Cellular Neuroscience 24, 1027-1037. doi: https://doi.org/10.1016/j.mcn.2003.08.005
Herrero, J. A. (2010). Tendencias y perspectivas del sector forestal hasta el año 2020. República de Cuba. Ministerio de la Agricultura. Dirección Forestal. ftp://ftp.fao.org/docrep/fao/009/a0470s/a0470s00.pdf
Hossmann, K. A. (1994). Viability thresholds and the penumbra of focal ischemia. Annals of Neurology 36, 557-65. doi: https://doi.org/10.1002/ana.410360404
Kwakkel, G., Kollen, B., & Lindeman E. (2004). Understanding the pattern of functional recovery after stroke: Facts and theories. Restorative Neurology and Neuroscience 22, 281-299. http://www.mendeley.com/research/understanding-pattern-functional-recovery-after-stroke-facts-theories/
Mergenthaler, P., Dirnagl, U., & Meisel, A. (2004). Pathophysiology of stroke: lessons from animal models. Metabolic Brain Disease 19(3/4), 102-112.
Millán, M. J. (2003). The neurobiology and control of anxious states. Progress in Neurobiology 70, 83-244. doi: https://doi.org/10.1016/S0301-0082(03)00087-X
Soza, T. I. (2007). Neuroprotección en la isquemia cerebral. Experiencias con la eritropoyetina humana recombinante. Revista Ecuatoriana de Neurología. 16(2), 63-75.
Panikashvili, D., Mechoulam, R., Beni, S. M., Alexandrovich, A., & Shohami, E. (2005). CB1 cannabinoid receptors are involved in neuroprotection via NF-B inhibition. Journal of Cerebral Blood Flow & Metabolism 25(4), 477-484.
Persson, L., Hårdemark, H. G., Bolander, H. G., Hillered, L., & Olsson, Y. (1998). Neurologic and neuropathologic outcome after middle cerebral artery occlusion in rats. Stroke 20, 641-645.
Piomelli, D. (2005). The endocannabinoid system: a drug discovery perspective. Curr Opin Investig Drugs 6(7), 672-679. http://www.mendeley.com/research/endocannabinoid-system-drug-discovery-perspective-1/
Siesjö, B. K. (1992). Pathophysiology and treatment of focal cerebral ischemia. Journal Neurosurgery 77, 169-84. http://chronopause.com/index.php/2011/02/12/the-pathophysiology-of-ischemic-injury-impact-on-the-human-cryopreservation-patient-part-2/
Tamura, A., Graham, D. I., McCulloch, J. & Teasdale, G. M. (1981). Focal cerebral ischemia in the rat: Description of technique and early neuropathological consequences following middel cerebral artery occlusion. Journal of Cerebral Blood Flow & Metabolism 1, 53-60 http://www.ncbi.nlm.nih.gov/pubmed/7328138
Van der Worp, H. B.; de Haan, P., Morrema, E. & Kalkman C. J. (2005). Methodological quality of animal studies on neuroprotection in focal cerebral ischaemia. Journal Neurology, 252, 1108-14. http://www.ncbi.nlm.nih.gov/pubmed/7328138
Viveros, M. P., Marco, E. M., & File, S. E. (2005). Endocannabinoid system and stress and anxiety responses. Pharmacology Biochemistry Behav. 81 (2), 331-42. http://www.ncbi.nlm.nih.gov/pubmed/15927244
Witkin, J. M., Tzavara, E. T., & Nomikos, G. G. (2005). A role for cannabinoid CB1 receptors in mood and anxiety disorders. Behavioural Pharmacology 16(5-6), 315-331. http://journals.lww.com/behaviouralpharm/Abstract/2005/09000/A_role_for_cannabinoid_CB1_receptors_in_mood_and.5.aspx
Wotjak, C. T. (2005). Role of endogenous cannabinoids in cognition and emotionality. Mini-Reviews in Medicinal Chemistry 5(7) ,659-670.
WHO, (World Health Organization) (2010). Prevention of mental disorders: Effective interventions and policy options: abridged report / a report of the World Health organization. Research Center at the Universities of Nijmegen and Maastricht.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright (c) 2012 Revista Chapingo Serie Ciencias Forestales y del Ambiente